These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24721980)

  • 1. Reducing communication delays and improving quality of care with a tuberculosis laboratory information system in resource poor environments: a cluster randomized controlled trial.
    Blaya JA; Shin SS; Yagui M; Contreras C; Cegielski P; Yale G; Suarez C; Asencios L; Bayona J; Kim J; Fraser HS
    PLoS One; 2014; 9(4):e90110. PubMed ID: 24721980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Full impact of laboratory information system requires direct use by clinical staff: cluster randomized controlled trial.
    Blaya JA; Shin S; Contreras C; Yale G; Suarez C; Asencios L; Kim J; Rodriguez P; Cegielski P; Fraser HS
    J Am Med Inform Assoc; 2011; 18(1):11-6. PubMed ID: 21113076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A web-based laboratory information system to improve quality of care of tuberculosis patients in Peru: functional requirements, implementation and usage statistics.
    Blaya JA; Shin SS; Yagui MJ; Yale G; Suarez CZ; Asencios LL; Cegielski JP; Fraser HS
    BMC Med Inform Decis Mak; 2007 Oct; 7():33. PubMed ID: 17963522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electronic laboratory system reduces errors in National Tuberculosis Program: a cluster randomized controlled trial.
    Blaya JA; Shin SS; Yale G; Suarez C; Asencios L; Contreras C; Rodriguez P; Kim J; Cegielski P; Fraser HS
    Int J Tuberc Lung Dis; 2010 Aug; 14(8):1009-15. PubMed ID: 20626946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of establishing a biosafety level 3 tuberculosis culture laboratory of acceptable quality standards in a resource-limited setting: an experience from Uganda.
    Ssengooba W; Gelderbloem SJ; Mboowa G; Wajja A; Namaganda C; Musoke P; Mayanja-Kizza H; Joloba ML
    Health Res Policy Syst; 2015 Jan; 13():4. PubMed ID: 25589057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience establishing tuberculosis laboratory capacity in a developing country setting.
    Paramasivan CN; Lee E; Kao K; Mareka M; Kubendiran G; Kumar TA; Keshavjee S; Satti H; Alabi G; Raviglione M; Roscigno G
    Int J Tuberc Lung Dis; 2010 Jan; 14(1):59-64. PubMed ID: 20003696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance of programmatic and laboratory-based multidrug-resistant tuberculosis treatment outcomes in Peru.
    Alexy ER; Podewils LJ; Mitnick CD; Becerra MC; Laserson KF; Bonilla C
    Int J Tuberc Lung Dis; 2012; 16(3):364-9. PubMed ID: 22640451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing effects of the e-Chasqui laboratory information system on accuracy and timeliness of bacteriology results in the Peruvian tuberculosis program.
    Blaya JA; Shin SS; Yagui MJ; Yale G; Suarez C; Asencios L; Fraser H
    AMIA Annu Symp Proc; 2007 Oct; ():873. PubMed ID: 18693974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.
    Mitnick C; Bayona J; Palacios E; Shin S; Furin J; Alcántara F; Sánchez E; Sarria M; Becerra M; Fawzi MC; Kapiga S; Neuberg D; Maguire JH; Kim JY; Farmer P
    N Engl J Med; 2003 Jan; 348(2):119-28. PubMed ID: 12519922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician-initiated courtesy MODS testing for TB and MDR-TB diagnosis and patient management.
    Nic Fhogartaigh CJ; Vargas-Prada S; Huancaré V; Lopez S; Rodríguez J; Moore DA
    Int J Tuberc Lung Dis; 2008 May; 12(5):555-60. PubMed ID: 18419892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tuberculosis Laboratory Surveillance Network (TuLSA) study group. The first step for national tuberculosis laboratory surveillance: Ankara, 2011].
    Sezen F; Albayrak N; Özkara Ş; Karagöz A; Alp A; Duyar Ağca F; İnan Süer A; Müderris T; Ceyhan İ; Durmaz R; Ertek M;
    Mikrobiyol Bul; 2015 Apr; 49(2):143-55. PubMed ID: 26167815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid drug susceptibility testing and treatment outcomes for multidrug-resistant tuberculosis in Peru.
    Obregón G; Zevallos K; Alarcón V; Puyén ZM; Chávez Inagaki O; Mendoza-Ticona A; Alarcón-Arrascue E; Heldal E; Moore DAJ
    Int J Tuberc Lung Dis; 2018 Nov; 22(11):1350-1357. PubMed ID: 30355416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MODS accreditation process for regional reference laboratories in Peru: validation by GenoType® MTBDRplus.
    Coronel J; Roper M; Mitchell S; Castillo E; Gamarra N; Drobniewski F; Luna G; Mendoza A; Moore DA
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1475-80. PubMed ID: 20937190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved treatment outcome of multidrug-resistant tuberculosis with the use of a rapid molecular test to detect drug resistance in China.
    Shi W; Davies Forsman L; Hu Y; Zheng X; Gao Y; Li X; Jiang W; Bruchfeld J; Diwan VK; Hoffner S; Xu B
    Int J Infect Dis; 2020 Jul; 96():390-397. PubMed ID: 32353546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru.
    Magee MJ; Bloss E; Shin SS; Contreras C; Huaman HA; Ticona JC; Bayona J; Bonilla C; Yagui M; Jave O; Cegielski JP
    Int J Infect Dis; 2013 Jun; 17(6):e404-12. PubMed ID: 23434400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru.
    Chavez Pachas AM; Blank R; Smith Fawzi MC; Bayona J; Becerra MC; Mitnick CD
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):52-8. PubMed ID: 14974746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance among tuberculosis cases in the European Union and European Economic Area, 2007 to 2012.
    van der Werf MJ; Ködmön C; Hollo V; Sandgren A; Zucs P
    Euro Surveill; 2014 Mar; 19(10):. PubMed ID: 24650865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil.
    Ramalho DMP; Miranda PFC; Andrade MK; Brígido T; Dalcolmo MP; Mesquita E; Dias CF; Gambirasio AN; Ueleres Braga J; Detjen A; Phillips PPJ; Langley I; Fujiwara PI; Squire SB; Oliveira MM; Kritski AL;
    BMC Infect Dis; 2017 Aug; 17(1):571. PubMed ID: 28810911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.